Nothing Special   »   [go: up one dir, main page]

PE20150190A1 - Formulacion farmaceutica - Google Patents

Formulacion farmaceutica

Info

Publication number
PE20150190A1
PE20150190A1 PE2014002385A PE2014002385A PE20150190A1 PE 20150190 A1 PE20150190 A1 PE 20150190A1 PE 2014002385 A PE2014002385 A PE 2014002385A PE 2014002385 A PE2014002385 A PE 2014002385A PE 20150190 A1 PE20150190 A1 PE 20150190A1
Authority
PE
Peru
Prior art keywords
pharmaceutical formulation
antibody
present
high concentration
formulation including
Prior art date
Application number
PE2014002385A
Other languages
English (en)
Inventor
Andrew Jeffrey Yates
James Gregory Clipstone
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of PE20150190A1 publication Critical patent/PE20150190A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A METODOS Y MEDIOS PARA REDUCIR LA VISCOSIDAD DE UNA FORMULACION FARMACEUTICA QUE COMPRENDE UN ANTICUERPO U OTRA PROTEINA TERAPEUTICA A UNA ELEVADA CONCENTRACION. LA PRESENTE INVENCION PROPORCIONA UNA FORMULACION FARMACEUTICA LIQUIDA QUE COMPRENDE UN ANTICUERPO A CONCENTRACION ELEVADA CON UNA VISCOSIDAD REDUCIDA QUE NO IMPIDE SU PROCESAMIENTO NI LA INYECCION DE LA FORMULACION FARMACEUTICA. EL ANTICUERPO ES EPRATUZUMAB A UNA CONCENTRACION DE 200 A 400 MG/ML
PE2014002385A 2012-06-21 2013-06-20 Formulacion farmaceutica PE20150190A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21

Publications (1)

Publication Number Publication Date
PE20150190A1 true PE20150190A1 (es) 2015-02-13

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002385A PE20150190A1 (es) 2012-06-21 2013-06-20 Formulacion farmaceutica

Country Status (25)

Country Link
US (1) US20150150979A1 (es)
EP (1) EP2864356A1 (es)
JP (1) JP6157611B2 (es)
KR (1) KR20150032941A (es)
CN (1) CN104520326A (es)
AR (1) AR091530A1 (es)
AU (1) AU2013279347A1 (es)
BR (1) BR112014031841A2 (es)
CA (1) CA2876012A1 (es)
CL (1) CL2014003283A1 (es)
CO (1) CO7170174A2 (es)
EA (1) EA201590061A1 (es)
EC (1) ECSP15002095A (es)
HK (1) HK1205146A1 (es)
IL (1) IL235921A0 (es)
MA (1) MA37777B1 (es)
MX (1) MX2014014717A (es)
NZ (1) NZ702342A (es)
PE (1) PE20150190A1 (es)
PH (1) PH12014502596A1 (es)
SG (1) SG11201407779YA (es)
TN (1) TN2014000498A1 (es)
TW (1) TW201406398A (es)
WO (1) WO2013190047A1 (es)
ZA (1) ZA201409020B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043774T1 (sl) 2013-09-11 2021-01-29 Eagle Biologics, Inc. Tekoče proteinske formulacije, ki vsebujejo ionske tekočine
SG10201902915VA (en) 2014-10-01 2019-04-29 Eagle Biologics Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US11738036B2 (en) 2016-05-28 2023-08-29 Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Biotechnology, Government Of India Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma
ES2882181T3 (es) * 2016-10-31 2021-12-01 Fresenius Kabi Deutschland Gmbh Composición farmacéutica líquida
US10980881B2 (en) 2017-01-11 2021-04-20 Celltrion Inc. Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine
SG11202003754YA (en) 2017-05-16 2020-05-28 Bhamis Research Laboratory Pvt Ltd High concentration protein formulations with reduced viscosity
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EP4247386A1 (en) * 2020-11-18 2023-09-27 Bexson Biomedical, Inc. Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1324776T4 (en) * 2000-10-12 2018-05-28 Genentech Inc CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
ES2609010T3 (es) * 2003-04-04 2017-04-18 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
WO2006096491A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-ctla-4 antibody compositions
MX2009007406A (es) * 2007-01-09 2010-01-25 Wyeth Corp Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
ES2707815T3 (es) * 2007-06-14 2019-04-05 Biogen Ma Inc Formulaciones de anticuerpo natalizumab
RU2012151500A (ru) * 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
PL2569010T3 (pl) * 2010-05-14 2017-09-29 Amgen, Inc Wysoce stężone preparaty przeciwciał
SG186421A1 (en) * 2010-07-02 2013-01-30 Medimmune Llc Antibody formulations
AU2012243126A1 (en) * 2011-04-07 2013-10-17 Glaxosmithkline Llc Formulations with reduced viscosity
CN103501825B (zh) * 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩

Also Published As

Publication number Publication date
PH12014502596A1 (en) 2015-01-12
AR091530A1 (es) 2015-02-11
MA20150436A1 (fr) 2015-11-30
HK1205146A1 (en) 2015-12-11
US20150150979A1 (en) 2015-06-04
ZA201409020B (en) 2016-09-28
MX2014014717A (es) 2015-03-06
BR112014031841A2 (pt) 2017-06-27
CN104520326A (zh) 2015-04-15
NZ702342A (en) 2016-07-29
TN2014000498A1 (en) 2016-03-30
SG11201407779YA (en) 2015-02-27
EA201590061A1 (ru) 2015-05-29
WO2013190047A1 (en) 2013-12-27
CA2876012A1 (en) 2013-12-27
JP6157611B2 (ja) 2017-07-05
CL2014003283A1 (es) 2016-04-01
EP2864356A1 (en) 2015-04-29
MA37777B1 (fr) 2017-07-31
IL235921A0 (en) 2015-01-29
JP2015520206A (ja) 2015-07-16
KR20150032941A (ko) 2015-03-31
AU2013279347A1 (en) 2014-12-18
TW201406398A (zh) 2014-02-16
ECSP15002095A (es) 2015-11-30
CO7170174A2 (es) 2015-01-28

Similar Documents

Publication Publication Date Title
PE20150190A1 (es) Formulacion farmaceutica
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
BR112018002196A2 (pt) formulação anti-ifnar1 estável
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
AR098168A1 (es) Formulación estable de insulina glulisina
GT201400285A (es) Formulacion de anticuerpos
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
CO7270463A2 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112019023981A2 (pt) injeção de octreotida
CL2016000944A1 (es) Nueva formulación de ganadotropinas
BR112014021870A2 (pt) formulação de anticorpos anti-selectina p

Legal Events

Date Code Title Description
FD Application declared void or lapsed